NLS Pharmaceutics (NASDAQ:NCEL) versus Eupraxia Pharmaceuticals (NASDAQ:EPRX) Head-To-Head Review

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Eupraxia Pharmaceuticals and NLS Pharmaceutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58 million	($1.05)	-6.10
NLS Pharmaceutics	N/A	N/A	-$8.30 million	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Eupraxia Pharmaceuticals and NLS Pharmaceutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1	1	5	2	2.89
NLS Pharmaceutics	1	0	1	0	2.00

Eupraxia Pharmaceuticals presently has a consensus target price of $18.00, indicating a potential upside of 181.25%. NLS Pharmaceutics has a consensus target price of $23.00, indicating a potential upside of 559.03%. Given NLS Pharmaceutics’ higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Eupraxia Pharmaceuticals.

Profitability

This table compares Eupraxia Pharmaceuticals and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
NLS Pharmaceutics	N/A	N/A	N/A

Volatility and Risk

Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.